| Literature DB >> 25013457 |
Stefanie Bug1, Beate Solfrank1, Felizitas Schmitz1, Jana Pricelius1, Mona Stecher1, Andrew Craig2, Marc Botcherby2, Claudia Nevinny-Stickel-Hinzpeter1.
Abstract
BACKGROUND: This proof-of-principle study demonstrates the usefulness and robustness of a novel array based method for the elucidation of genetic causes underlying early pregnancy loss. A combined microarray utilizing comparative genomic hybridization and single nucleotide polymorphism detection (CGH + SNP) was used for parallel genome-wide identification of copy number and heterozygosity status of 70 products of conception. Results of samples with previously determined aneuploidies were juxtaposed to those of a second cohort appearing normal after routine genetic diagnostics.Entities:
Keywords: Aneuploidy; Combined microarray; Early pregnancy loss; Genetic diagnostics; Loss of heterozygosity; Product of conception
Year: 2014 PMID: 25013457 PMCID: PMC4090657 DOI: 10.1186/1755-8166-7-43
Source DB: PubMed Journal: Mol Cytogenet ISSN: 1755-8166 Impact factor: 2.009
Juxtaposition of conventional CGH- and SNP-array techniques to the combined approach chosen in this study
| One target consists of one 60mer oligonucleotide | Allele-specific 60mer olionucleotide targets, arranged in quartets differing in a single base each are arranged for SNP-detection | CGH + SNP-arrays contain both kinds of probes | |
| Copy number aberrations | Copy number and copy number neutral deviations (LOH) | Copy number and copy number neutral deviations (LOH) | |
| Comparative hybridization with a reference sample | Sample hybridization only | Comparative hybridization with a reference sample | |
| Copy number determination by comparison with a diploid reference sample | Determination of heterozygosity status by measuring of A- and B-alleles and | Combined detection: Only one allele is measured, the total number of alleles at given loci are estimated from CGH-probe signals |
Figure 1Genome-wide CGH and SNP hybridization profiles for a sample displaying trisomy 4. Panel A: aCGH data, CN: copy number, Panel B: SNP data, GT: genotype.
Comparison of results obtained in the current study and results from diagnostic routine
| Native villi | Proliferation in cell culture | 1 | 45,X | arr (X)×1 | Yes | |
| 2 | 45,X | arr (X)×1 | Yes | |||
| 3 | 45,X | arr (X)×1 | Yes | |||
| 4 | 45,X | arr (X)×1 | Yes | |||
| 5 | 47,XX,+7 | arr (7)×3 | Yes | |||
| 6 | 47,XX,+7 | arr (7)×3 | Yes | |||
| 7 | 47,XX,+10 | arr (10)×3 | Yes | |||
| 8 | 47,XX,+12 | arr (10)×3 | Yes | |||
| 9 | 47,XX,+12 | arr (12)×3,(X)×1 | Yes, additionally monosomy X detected | |||
| 10 | 47,XX,+14 | arr (14)×3 | Yes | |||
| 11 | 47,XX,+15 | arr (15)×3 | Yes | |||
| 12 | 47,XX,+15 | arr (15)×3 | Yes | |||
| 13 | 47,XX,+16 | arr (16)×3 | Yes | |||
| 14 | 47,XY,+16 | arr (16)×3 | Yes | |||
| 15 | 47,XY,+16 | arr (16)×3 | Yes | |||
| 16 | 47,XX,+18 | arr (18)×3 | Yes | |||
| 17 | 47,XY,+20 | arr (20)×3 | Yes | |||
| 18 | 47,XY,+21 | arr (21)×3 | Yes | |||
| 19 | 47,XX,+21 | arr (21)×3 | Yes | |||
| 20 | 47,XX,+22 | arr (22)×3 | Yes | |||
| 21 | 47,XX,+22 | arr (22)×3 | Yes | |||
| 22 | 47,XY,+22 | arr (22)×3 | Yes | |||
| 23 | 48,XX,+6,+10 | arr (6)×3,(10)×3 | Yes | |||
| 24 | 48,XX,+7,+16 | arr (7)×3,(16)×3 | Yes | |||
| 25 | 48,XY,+14,+20 | arr (14)×3,(20)×3 | Yes | |||
| 26 | 48,XX,+18,+22 | arr (18)×3,(22)×3 | Yes | |||
| 27 | 49,XX,+13,+16,+21 | arr (13)×3,(16)×3,(21)×3 | Yes | |||
| 28 | 68,XXY,-11 | arr (X)×1 ~ 2 | No, gonosome profile indicates polyploidy, but loss of chr. 11 was missed | |||
| 29 | 70,XXY,+21 | arr (21)×3,(X)×1 ~ 2 | Yes | |||
| 30 | 92,XXXX | arr (1–22,X)×2 | No, tetraploidy was missed | |||
| 31 | 92,XXXX | arr (1–22,X)×2 | No, tetraploidy was missed | |||
| Cell culture failure | 32 | arr (4)×3c | arr (4)×3 | Yes | ||
| 33 | arr (15)×3c,d | arr (15)×3 | Yes | |||
| 34 | arr (16)×3c | arr (16)×3 | Yes | |||
| 35 | arr (22)×3c | arr (22)×3 | Yes | |||
| Native villi | Proliferation in cell culture | 36 | 45,XY,rob (13;14) (q10;q10) | arr (1–22)×2,(XY)×1 | Yes | |
| 37 | 46,XX | arr (1–22,X)×2 hmz | Yes, additionally hydatidiform mole detected | |||
| 38 | 46,XY | arr 2p24.3 (12,849,885-15,823,789)×1 | Yes, additionally CNC detected | |||
| 39 | 46,XX | arr 6q23.2q24.31 (131,723,146-147,738,560)×2 hmz | Yes, AOH of uncertain clinical significance detected | |||
| 40 | 46,XY | arr 6q23.3q25.1 (135,836,902-150,015,258)×2 hmz | Yes, but false positive AOH call | |||
| 41 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 42 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 43 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 44 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 45 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 46 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 47 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 48 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 49 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 50 | 46,XY | arr (1–22)×2,(XY)×1 | Yes | |||
| 51 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 52 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 53 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 54 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 55 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 56 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 57 | 46,XX | arr (1–22,X)×2 | Yes | |||
| Cultured villi | 58 | 46,XX | arr (1–22,X)×2 | Yes | ||
| 59 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 60 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 61 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 62 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 63 | 46,XX | arr (1–22,X)×2 | Yes | |||
| 64 | 46,XX | arr (1–22,X)×2 | Yes | |||
| Native villi | Cell culture failure | 65 | nuc ish (DXZ1x2,D18Z1x2), (RB1x2,D16Z1x2,D18Z1x2,DSCRx2,BCRx2) | arr (1–22,X)×2 | Yes | |
| 66 | nuc ish (DXZ1x1,DYZ3x1,D18Z1x2), (RB1x2,D16Z3x2,DSCRx2,BCRx2) | arr (1–22)×2,(XY)×1 | Yes | |||
| 67 | arr (1–22,X)×2e | arr (1–22,X)×2 | Yes | |||
| 68 | arr (1–22)×2,(XY)×1c | arr (1–22)×2,(XY)×1 | Yes | |||
| 69 | arr (1–22)×2,(XY)×1c | arr (1–22)×2,(XY)×1 | Yes | |||
| NFa | 70 | arr (1–22)×2,(XY)×1f | arr (1–22)×2,(XY)×1 | Yes |
aNF: native fetal.
baccording to ISCN 2013 [35].
c4x180K (Agilent Technologies, Santa Clara, USA).
d8x60K (Agilent Technologies, Santa Clara, USA).
e24sure (BlueGnome, Ltd., Cambridge, UK).
f4x44K (Agilent Technologies, Santa Clara, USA).